A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer

Oncology

Volumn 71, Issue 3-4, 2007, Pages 306-308

  Goldman, Matthew L ^a   Denduluri, Neelima ^a   Berman, Arlene W ^a   Sausville, Rebecca ^a   Guadagnini, Jean Pierre ^a   Kleiner, David E ^b   Brahim, Jaime S ^c   Swain, Sandra M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Bisphosphonate toxicity; Jaw osteonecrosis; Maxillary exostosis; Torus palatinus; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IXABEPILONE; PREDNISONE; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DISEASE PREDISPOSITION; DRUG WITHDRAWAL; EXOSTOSIS; FEMALE; HUMAN; JAW; MAXILLA; MOUTH HYGIENE; MOUTH PAIN; PALATINE TORUS; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; EXOSTOSES; FEMALE; HUMANS; IMIDAZOLES; MAXILLA; MIDDLE AGED; OSTEONECROSIS; PALATE, HARD;

EID: 34548103254     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106451     Document Type: Article

References (11)

1. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
2. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
3. Kuehn BM: Reports of adverse events from bone drugs prompt caution. JAMA 2006;295:2833-2836.
4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papa dimitriou C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
5. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C: Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-123.
6. Shah DS, Sanghavi SJ, Chawda JD, Shah RM: Prevalence of torus palatinus and torus mandibularis in 1,000 patients. Indian J Dent Res 1992;3:107-110.
7. Al-Bayaty HF, Murti PR, Matthews R, Gupta PC: An epidemiological study of tori among 667 dental outpatients in Trinidad & Tobago, West Indies. Int Dent J 2001;51:300-304.
8. Belsky JL, Hamer JS, Hubert JE, Insogna K, Johns W: Torus palatinus: a new anatomical correlation with bone density in postmenopausal women. J Clin Endocrinol Metab 2003;88:2081-2086.
9. Ruggiero S, Fralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V: Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14.
10. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T: Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-952.
11. Migliorati CA, Schubert MM, Peterson DE, Seneda LM: Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.